Insurance Denied Crohn's or Colitis Treatment — How to Fight Back

Living with Crohn's disease or ulcerative colitis means living with unpredictability — flares that derail your life, symptoms that are deeply personal and disruptive, and the constant work of managing a chronic illness. When your gastroenterologist finally finds the right treatment and your insurance denies it, that betrayal cuts deep. You are not being difficult. You are not asking for too much. And the denial is not final. Here is what you need to know to fight back.

Why Insurers Deny IBD Treatment

Inflammatory bowel disease (IBD) biologics — including infliximab (Remicade), adalimumab (Humira), vedolizumab (Entyvio), ustekinumab (Stelara), and newer small molecules like upadacitinib (Rinvoq) — are among the most commonly denied specialty medications. Denial reasons include:

• Step therapy requirements: Insurers insist you fail on older, cheaper medications (like corticosteroids, azathioprine, or 6-mercaptopurine) before approving biologics — even when those drugs have already failed or are medically inappropriate.
• "Experimental" or "not medically necessary": Some plans still question biologics despite decades of evidence and FDA approval.
• Off-label use: Certain newer agents may be approved for one indication (e.g., ulcerative colitis) but prescribed for another (e.g., Crohn's) where evidence is strong but the label differs.
• Specialty pharmacy restrictions: Insurer requires you use a specific pharmacy for infusions or self-injectable drugs.
• Dose escalation denied: You've responded to a biologic but need a dose increase — which insurers sometimes deny as a "new" request.

Clinical Guidelines Supporting Your Appeal

The American College of Gastroenterology (ACG) and the Crohn's & Colitis Foundation both publish comprehensive clinical practice guidelines that form the backbone of a strong appeal:

• ACG guidelines support biologic therapy as a first-line option for moderate-to-severe Crohn's and UC — not as a last resort after step therapy failure.
• The STRIDE-II guidelines (Selecting Therapeutic Targets in IBD) define treat-to-target endpoints including mucosal healing, symptom resolution, and biomarker normalization — all of which support the use of advanced therapies.
• For patients with fistulizing Crohn's, perianal disease, or extraintestinal manifestations, specific biologics (particularly anti-TNF agents) are the standard of care.

If your insurer is invoking step therapy, gather documentation of any prior medication trials: what you took, for how long, and why it failed. Gastroenterologists routinely write letters explaining that further delay of advanced therapy risks disease progression, hospitalization, or surgery.

Structuring Your Appeal

An effective appeal for Crohn's or colitis denial should include:

1. Gastroenterologist's letter of medical necessity — specifying disease severity (Harvey-Bradshaw Index for Crohn's or Mayo Score for UC), endoscopic findings, and clinical rationale for the specific drug requested.
2. Endoscopy or colonoscopy reports showing active inflammation, ulceration, or disease extent.
3. Lab results (CRP, fecal calprotectin, albumin) documenting inflammatory burden.
4. History of prior medication trials and documented failures or contraindications.
5. ACG clinical practice guidelines (cite the specific publication) supporting the requested therapy.

If the denial cites experimental status, attach FDA approval documentation for the drug and relevant published trials. If step therapy is the barrier, cite your state's step therapy override law.

The Real Cost of Delay

Untreated or undertreated IBD leads to hospitalizations, bowel resections, and long-term complications including strictures, fistulas, and colorectal cancer risk. Making this argument explicit in your appeal — backed by your physician's clinical assessment — demonstrates that the insurer's denial is not cost-saving but cost-shifting: onto the system, and onto you.

Advocacy and Support Resources

• Crohn's & Colitis Foundation (crohnscolitisfoundation.org) — has an IBD helpline and insurance assistance resources
• Patient Advocate Foundation (patientadvocate.org) — case managers who specialize in insurance denials
• NeedyMeds (needymeds.org) — patient assistance programs for biologic medications
• Biologic manufacturers (AbbVie, Janssen, Takeda) all have patient support programs with insurance navigation assistance

Request an External Independent Review: Complete Guide" class="auto-link">External Review

If your internal appeal fails, immediately request an external independent medical review. An independent gastroenterologist reviewing your case is very likely to support the need for biologic therapy given the weight of published evidence. External reviews for IBD are frequently resolved in the patient's favor.

Fight Back With ClaimBack

You deserve treatment that controls your IBD — not a bureaucratic delay that lets inflammation damage your bowel while paperwork piles up. ClaimBack helps IBD patients build compelling, clinically grounded appeal letters tailored to your specific denial reason.

Start your appeal now at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied